The ISH Meeting is held every other year to advance a global understanding of the progress made toward the treatment of hypertension and to promote an awareness of the challenges confronting the field of hypertension. Topics presented included the identification and treatment of the disease, risk stratification, cost-effective treatments, and a reduction in cardiovascular risk. More than 3,500 research scientists, physicians and other health care professionals from around the world attended this meeting.

Two detailed displays were presented by investigators who used the HDI/PulseWave™ CR-2000 Research CardioVascular Profiling System in their clinical research. Dr. L. Michael Prisant (Hypertension Unit, Section of Cardiology, Medical College of Georgia, Augusta, GA) and colleagues reported on the strong repeatability of immediate and intermediate measures of large and small arterial compliance, cardiac output and systemic vascular resistance with the HDI/PulseWave™ CR-2000 System in a presentation entitled: "Measures of capacitive and reflective compliance: Relationship to blood pressure parameters." Dr. L.M. Resnick (Hypertension Center, N.Y. - Presbyterian-Cornell Medical Center, N.Y.) and a clinical associate reported in a presentation entitled "Differential effects of anti-hypertensive drug therapy on ‘arterial’ compliance," that arterial elasticity improves with the administration of some, but not all, antihypertensive drugs, and that such improvement appears to offer greater benefit clinically.

The ISH Special Satellite Symposium, chaired by Dr. Jay N. Cohn, focused on the "Structure and Function of the Arterial Wall." A clear understanding of the various factors that impact the structure and function of the artery wall has only recently begun to emerge. Key investigators from around the world presented the most recent information in this area including the significance of the newest findings for both future research as well as clinical application. Eight of the presenters at this symposium are current users of HDI’s CR-2000 technology. "The scientific presentations at this meeting represented the most advanced thinking in blood vessel research – worldwide. Many of the participants requested an annual meeting such as this, something I have promised to pursue," said Dr. Cohn.

HDI also had a presence at the XXII^nd Congress of the European Society of Cardiology for the first time this year. The ESC Meeting attracts more than 20,000 cardiologists, research scientists and other health care providers. The mission of the ESC is to improve the quality of life in the European population by reducing the impact of cardiovascular disease. The HDI/PulseWave™ CR-2000 Research System was well received by many cardiologists since the System non-invasively provides research information on both large and small arterial elasticity that is otherwise unavailable.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 1999 Annual Report on Form 10-KSB under the caption "Risk Factors", as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company’s ability to receive regulatory approval for its CVProfilor^® DO-2020 CardioVascular Profiling System; the availability of third-party reimbursements; and market acceptance of the Company’s products.

Hypertension Diagnostics, CVProfilor^® and HDI/PulseWave™ are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President